advanced or reccurent esophageal cancer
Conditions
Interventions
Paclitaxel (100mg/m2) is administered intravenously over 1 h on days 1, 8 and 15 of each 4-week period.
Sponsors
Medical Oncology, Hirosaki University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: older than 20 years of age with histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the esophagus, and who had received at least one regimen of platinum-based chemotherapy advanced (stage IV) or recurrent (after chemotherapy, surgery or radiotherapy) disease previous platinum-based chemotherapy could have occurred in the adjuvant or neoadjuvant setting, or in combination with radiotherapy patients had either failed or progressed (stage IV) following platinum-based therapy, or had discontinued due to toxicity patients with measurable disease ECOG PS of 0 or 1, and a life expectancy of 3 months treatment interval longer than 3 weeks adequate functioning of major organ systems as indicated by the following laboratory parameters: neutrophils >=1,500/mm3; platelets >=100,000/mm3; hemoglobin >=9 g/dL; ALT and AST levels <=100 IU/L; total bilirubin <=1.5 mg/dL; and serum creatinine <=1.5 mg/dL written informed consent was obtained from all patients
Exclusion criteria
Exclusion criteria: severe bone marrow suppression active infection uncontrolled comorbidities acute inflammatory disease interstitial pneumonia or pulmonary fibrosis symptomatic metastases of the central nervous system with a history of allergic reaction to polyoxyethylene-castor oil under administration of disulfiram, cyanamide and procarbazine hydrochloride pregnant or nursing woman any patients judged by the investigator to be unfit to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate | — |
Countries
Japan
Contacts
Public Contactatsushi sato
Hirosaki University Graduate School of Medicine Medical Oncology
Outcome results
None listed